Tirbanibulin Patent Expiration
Tirbanibulin is Used for treating actinic keratosis on the face or scalp. It was first introduced by Almirall Llc
Tirbanibulin Patents
Given below is the list of patents protecting Tirbanibulin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Klisyri | US10669236 | Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide | Sep 07, 2038 | Almirall |
| Klisyri | US10617693 | Methods of treating and/or preventing actinic keratosis | Mar 12, 2038 | Almirall |
| Klisyri | US11497750 | Methods of treating and/or preventing actinic keratosis | Mar 12, 2038 | Almirall |
| Klisyri | US12667576 | Methods Of Treating And/Or Preventing Actinic Keratosis | Mar 12, 2038 | Almirall |
| Klisyri | US7300931 | Compositions for treating cell proliferation disorders | Dec 28, 2030 | Almirall |
| Klisyri | US7851470 | Composition and methods for modulating a kinase cascade | Feb 02, 2029 | Almirall |
| Klisyri | US10323001 | Compositions for modulating a kinase cascade and methods of use thereof | Dec 28, 2027 | Almirall |
| Klisyri | US8236799 | Biaryl compositions and methods for modulating a kinase cascade |
Dec 28, 2025
(Expired) | Almirall |
| Klisyri | US8980890 | Compositions and methods of treating cell proliferation disorders |
Dec 28, 2025
(Expired) | Almirall |
Tirbanibulin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tirbanibulin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead | University Hospital, Lille | NA |
NOT YET RECRUITING
(May 1, 2026)
| PHASE3 |
| A Study to Evaluate the Efficacy and Safety of Tirbanibulin Ointment in Adult Participants With Actinic Keratosis | Almirall, S.A. | NA |
COMPLETED
(Mar 1, 2026)
| PHASE3 |